Rabies vaccination at a virus-inoculated site as an alternative option to rabies immunoglobulin

Archives of Virology

Volumn 161, Issue 9, 2016, Pages 2537-2541

  Morimoto, Kinjiro ^a   Khawplod, Pakamatz ^b   Sato, Yuichiro ^a   Virojanapirom, Phatthamon ^c   Hemachudha, Thiravat ^c  

^a YASUDA WOMEN'S UNIVERSITY   (Japan)

^b THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^c CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Post exposure prophylaxis (PEP); Rabies; Virus neutralizing antibody (VNA)

Indexed keywords

IMMUNOGLOBULIN; RABIES VACCINE;

ANIMAL; HAMSTER; IMMUNOLOGY; MORTALITY; POST EXPOSURE PROPHYLAXIS; RABIES; RABIES VIRUS;

ANIMALS; CRICETINAE; IMMUNOGLOBULINS; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; RABIES VIRUS;

EID: 84976320097     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-016-2916-6     Document Type: Article

References (28)

1. World Health Organization (Geneva) (2013) WHO expert consultation on rabies. WHO Technical Report Series 982
2. Müller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, Kliemt J, Meslin FX, Franka R, Rupprecht CE, Tordo N, Wanderler AI, Kieny MP (2009) Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis 3(11):e542. doi:10.1371/journal.pntd.0000542
3. Wilde H, Tipkong P, Khawplod P (1999) Economic issue in post-exposure rabies treatment. J Travel Med 6(4):238–242
4. Wilde H, Lumlertdacha B, Meslin FX, Ghai S, Hemachudha T (2015) Worldwide rabies deaths prevention-A focus on the current inadequacies in postexposure prophylaxis of animal bite victims. Vaccine 34(2):187–189. doi:10.1016/j.vaccine.2015.11.036
5. Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB (1990) Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 335(8694):896–898
6. Saraya A, Wacharapluesadee S, Khawplod P, Tepsumethanon S, Briggs D, Asawavichienjinda T, Hemachudha T (2010) A preliminary study of chemo- and cytokine responses in rabies vaccine recipients of intradermal and intramuscular regimens. Vaccine 28(29):4553–4557
7. Virojanapirom P, Khawplod P, Sawangvaree A, Wacharapluesadee S, Hemachudha T, Yamada K, Morimoto K, Nishizono A (2012) Molecular analysis of the mutational effects of Thai street rabies virus with increased virulence in mice after passages in the BHK cell line. Arch Virol 157(11):2201–2205. doi:10.1007/s00705-012-1402-z
8. Smith JS, Yager PA, Baer GM (1996) A rapid fluorescent focus inhibition test (RFFIT) for determining rabies virus-neutralising antibody. In: Meslin FX, Kaplan MM, Koprowski H (eds) Laboratory techniques in rabies, 4th edn. World Health Organization, Geneva, pp 181–192
9. Tantawichien T, Benjavongkulchai M, Limsuwan K, Khawplod P, Kaewchompoo W, Chomchey P, Sitprija V (1999) Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. Clin Infect Dis 28(5):1100–1103
10. World Health Organization (Geneva) Rabies vaccines WHO position paper (2007) Weekly Epidemiological Record No. 49/50, pp 425–436
11. Sarmento L, Li XQ, Howerth E, Jackson AC, Fu ZF (2005) Glycoprotein-mediated induction of apoptosis limits the spread of attenuated rabies viruses in the central nervous system of mice. J Neurovirol 11(6):571–581
12. Li J, McGettigan JP, Faber M, Schnell MJ, Dietzschold B (2008) Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFκB signaling pathway. Vaccine 26(3):419–426
13. Kuang Y, Lackay SN, Zhao L, Fu ZF (2009) Role of chemokines in the enhancement of BBB permeability and inflammatory infiltration after rabies virus infection. Virus Res 144(1–2):18–26. doi:10.1016/j.virusres.2009.03.014
14. Lafon M (2011) Evasive strategies in rabies virus infection. Adv Virus Res 79:33–53. doi:10.1016/B978-0-12-387040-7.00003-2
15. Menager P, Roux P, Megret F, Bourgeois JP, Le Sourd AM, Danckaert A, Lafage M, Prehaud C, Lafon M (2009) Toll-like receptor 3 (TLR3) plays a major role in the formation of rabies virus Negri Bodies. PLoS Pathog 5(2):e1000315. doi:10.1371/journal.ppat.1000315
16. Brzozka K, Finke S, Conzelmann KK (2005) Identification of the rabies virus alpha/beta interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J Virol 79(12):7673–7681. doi:10.1128/JVI.79.12.7673-7681.2005
17. Brzozka K, Finke S, Conzelmann KK (2006) Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J Virol 80(6):2675–2683. doi:10.1128/JVI.80.6.2675-2683.2006
18. Rieder M, Conzelmann KK (2011) Interferon in rabies virus infection. Adv Virus Res 79:91–114. doi:10.1016/B978-0-12-387040-7.00006-8
19. Vidy A, Chelbi-Alix M, Blondel D (2005) Rabies virus P protein interacts with STAT1 and inhibits interferon signal transduction pathways. J Virol 79(22):14411–14420. doi:10.1128/JVI.79.22.14411-14420.2005
20. Vidy A, El Bougrini J, Chelbi-Alix MK, Blondel D (2007) The nucleocytoplasmic rabies virus P protein counteracts interferon signaling by inhibiting both nuclear accumulation and DNA binding of STAT1. J Virol 81(8):4255–4263. doi:10.1128/JVI.01930-06
21. Moseley GW, Lahaye X, Roth DM, Oksayan S, Filmer RP, Rowe CL, Blondel D, Jans DA (2009) Dual modes of rabies P-protein association with microtubules: a novel strategy to suppress the antiviral response. J Cell Sci 122:3652–3662. doi:10.1242/jcs.045542
22. Chopy D, Pothlichet J, Lafage M, Megret F, Fiette L, Si-Tahar M, Lafon M (2011) Ambivalent role of the innate immune response in rabies virus pathogenesis. J Virol 85(13):6657–6668. doi:10.1128/JVI.00302-11
23. Miller A, Morse HC 3rd, Winkelstein J, Nathanson N (1978) The role of antibody in recovery from experimental rabies. I. Effect of depletion of B and T cells. J Immunol 121(1):321–326
24. Templeton JW, Holmberg C, Garber T, Sharp RM (1986) Genetic control of serum neutralizing-antibody response to rabies vaccination and survival after a rabies challenge infection in mice. J Virol 59(1):98–102
25. Xiang ZQ, Knowles BB, McCarrick JW, Ertl HC (1995) Immune effector mechanisms required for protection to rabies virus. Virology 214(2):398–404
26. Servat A, Lutsch C, Delore V, Lang J, Veitch K, Cliquet F (2003) Efficacy of rabies immunoglobulins in an experimental post-exposure prophylaxis rodent model. Vaccine 22(2):244–249
27. Dorfmeier CL, Tzvetkov EP, Gatt A, McGettigan JP (2013) Investigating the role for IL-21 in rabies virus vaccine-induced immunity. PLoS Negl Trop Dis 7(3):e2129. doi:10.1371/journal.pntd.0002129
28. Zhou M, Zhang G, Ren G, Gnanadurai CW, Li Z, Chai Q, Yang Y, Leyson CM, Wu W, Cui M, Fu ZF (2013) Recombinant rabies viruses expressing GM-CSF or flagellin are effective vaccines for both intramuscular and oral immunizations. PLoS One 8(5):e63384. doi:10.1371/journal.pone.0063384